n sometimes the FDA approves a drug for general use but requires the manufacturer to continue to monitor its effects; during this phase the drug may be tried on slightly different patient populations than those studied in earlier trials
AstraZeneca and BMY Drug Disappoints AstraZeneca and Bristol-Myers announced disappointing top-line data from a phase IV study on Onglyza
June 20, 2013 - Zacks via Yahoo! Finance
AstraZeneca and BMY Drug Disappoints - Analyst Blog AstraZeneca ( AZN ) and its partner Bristol-Myers Squibb Company ( BMY ) recently announced disappointing top-line data from a phase IV study (SAVOR-TIMI-53; n = 16,500) on their
June 20, 2013 - Nasdaq